Tongqing Chen

Prof. Dr. Tongqing Chen


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013
Verified
Journal Article
Closed access
TCTongqing Chen
Tongqing Chen
CCChang-Chun Chen
Chang-Chun Chen
JWJun-Xian Wang
Jun-Xian Wang
WCWen-Feng Chen
Wen-Feng Chen
XGXiao-Mei Gu
Xiao-Mei Gu
YZYan Zhao
Yan Zhao

26 August 2025 in Research Square
Verified
Preprint
Open access
PDF file
YZYalong Zhang
Yalong Zhang
XZXingguo Zhong
Xingguo Zhong
LZLin Zhou
Lin Zhou
YFYuan Fang
Yuan Fang
TCTongqing Chen
Tongqing Chen
Background Fructose-1,6-diphosphate (FDP), a metabolic intermediate widely used in clinical practice for managing ischemic conditions (e.g., myocardial infarction, hemorrhagic shock) due to its cytoprotective and ATP-enhancing properties, has poorly characterized effects on hemostasis. The current study aimed to systematically evaluate its in vitro impacts on coagulation and platelet function to address this knowledge gap. Methods Global hemostasis was assessed via thromboelastography (TEG) using three platforms (Maiketian, Lepu, Dingrun). Coagulation factor activities (II, V, VII, VIII, IX, X, XI, XII) were quantified with Sysmex CS5100. Platelet aggregation in platelet-rich plasma (PRP) from 5 healthy donors was tested with agonists (adenosine diphosphate [5 µmol/L], arachidonic acid [1 mmol/L], collagen [2.5 µg/mL], epinephrine [10 µmol/L]). Dose-response relationships (FDP: 0–6 mg/mL) were analyzed by linear regression. Results FDP prolonged TEG clot reaction time (R-time) concentration-dependently (P < 0.01). At therapeutic concentration (3.71 mg/mL), R-time increased by 21.8% (Maiketian), 48.3% (Lepu), and 34.1% (Dingrun) vs. controls (n=11). FDP inversely correlated with activities of factors V, VII, IX, XI, and XII (r = −0.989 to −0.997, all P < 0.001), but not factors II, VIII, X. FDP also inhibited platelet aggregation dose-dependently (maximal suppression: 94–95% at 6 mg/mL, P < 0.001), with epinephrine-induced aggregation most sensitive. Conclusions FDP exerts dual effects via selective inhibition of coagulation initiation factors and broad suppression of platelet aggregation. Caution is advised in high-risk populations (e.g., coagulation factor deficiencies, antithrombotic therapy). Further studies are needed to evaluate its clinical implications in anticoagulation therapy and bleeding risk.


27 February 2025 in medRxiv
Verified
Preprint
Open access
PDF file
YZYalong Zhang
Yalong Zhang
XZXingguo Zhong
Xingguo Zhong
LZLin Zhou
Lin Zhou
NHNing He
Ning He
YFYuan Fang
Yuan Fang
TCTongqing Chen
Tongqing Chen
Objective: To investigate the effects of sodium fructose diphosphate (FDP) on blood coagulation parameters, including reaction time and plasma coagulation factor activity, in both in vitro and in vivo models. Methods: Three thromboelastography systems (Maiketian, Lepu, Dingrun) were used to assess coagulation parameters (reaction time [R], clotting time [K], α-angle, maximal amplitude [MA]) in blood samples spiked with varying FDP concentrations. An automatic coagulation analyzer quantified the activities of coagulation factors II, V, VII, VIII, IX, X, XI, and XII in FDP-treated plasma.Differences between FDP-treated and control groups were statistically compared. Linear regression analyzed correlations between FDP concentrations and coagulation parameters. For in vivo studies, New Zealand white rabbits received intravenous FDP (0.5, 1, 2, or 4 g/kg), and thromboelastography parameters were monitored at multiple time points post-administration (0.5-2 hours). Results: Thromboelastography demonstrated a strong positive correlation between FDP concentration and R values across all systems ( P < 0.001; r = 0.988 [Maiketian], 0.999 [Lepu], 0.996 [Dingrun]). No significant associations were observed between FDP and K, α-angle, or MA ( P > 0.05). In vitro experiments revealed significant negative correlations between FDP concentration and activities of factors V ( r = -0.995), VII ( r = -0.990), IX ( r = -0.989), XI ( r = -0.997), and XII ( r = -0.995) ( P < 0.001), while factors II, VIII, and X remained unaffected ( P > 0.05). In vivo administration demonstrated dose-dependent prolongation of R-time, reaching statistical significance (p < 0.05) at:0.5 g/kg: 0.5 hr post-dose,1 g/kg: 0.5-1.5 hr,2 g/kg: 0.5-1.5 hr,4 g/kg: 0.5-2 hr. Conclusion: FDP significantly impacts coagulation testing outcomes both in vitro and in vivo, potentially through modulation of intrinsic pathway factors (V, VII, IX, XI, XII) and direct interference with clot initiation. These findings suggest clinically relevant anticoagulant properties that warrant further investigation.


5 January 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YZYalong Zhang
Yalong Zhang
XZXingguo Zhong
Xingguo Zhong
LZLin Zhou
Lin Zhou
YFYuan Fang
Yuan Fang
TCTongqing Chen
Tongqing Chen
While fructose-1,6-diphosphate (FDP) has been clinically applied in ischemic conditions, its comprehensive effects on hemostasis remain to be fully elucidated. This in vitro study examined the influence of FDP on coagulation and platelet function using thromboelastography (TEG) across three platforms, coagulation factor assays, and platelet aggregation tests over a concentration range of 0–6 mg/mL. The results revealed that FDP concentration-dependently prolonged TEG R-time ( P < 0.01), with an increase of 21.8–48.3% at the clinically relevant concentration of 3.71 mg/mL. Strong inverse correlations were observed between FDP concentration and the activities of factors V, VII, IX, XI, and XII ( r  = − 0.989 to − 0.997, P < 0.001), whereas factors II, VIII, and X remained unaltered. Furthermore, FDP significantly inhibited platelet aggregation ( P < 0.001), nearly abolishing epinephrine- and ADP-induced aggregation at 6 mg/mL under unbuffered conditions. pH-control experiments confirmed that the anticoagulant effects were FDP-specific, while the antiplatelet effects were primarily mediated by FDP with a partial pH-dependent component. These findings demonstrate that FDP possesses dual anticoagulant and antiplatelet properties through selective inhibition of coagulation initiation factors and broad suppression of platelet responsiveness, suggesting potential implications for clinical use in high-risk populations and warranting further investigation.